IL33 and inflammation: These animals developed spontaneous joint inflammation and cartilage destruction and the administration of IL-33 inhibited the TNF-α-induced bone destruction via the IL-33/ST2 axis, which was confirmed using an ST2 agonist antibody that triggered the same downstream regulators.